PatientsHCP
This site is for US Health Care Professionals only

ENTRESTO® has a proven safety profile comparable to an ACEi and an ARB1

PARADIGM-HF: ENTRESTO has safety comparable to enalapril in patients with HFrEF
Adverse reactions reported in ≥5% of patients treated with ENTRESTO in the double-blind period†
Adverse Reactions Graph

†Due to the run-in period, adverse event rates were lower than would be expected in practice.

No new safety signals were observed in patients with HFpEF* with LVEF below normal1
In PARAGON-HF, the safety of ENTRESTO was comparable to valsartan.

Download to see renal safety profile across 3 clinical trials

Download the Renal Safety Flashcard to learn more

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Definitions
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LAE, left atrial enlargement; LVH, left ventricular hypertrophy.

References
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-777.
3. Ibrahim NE, Song Y, Cannon CP, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019;6(4):784-792.
4. Virani SS, Alonso A, Aparicio HJ, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143:e1-e490.